<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with HER2-positive, metastatic breast cancer who previously received<unk>  and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.
Ado-trastuzumab emtansine
Vincristine liposome
Dasatinib
Afatinib
Neratinib
Radioimmunotherapy
Cytarabine liposome
Ibritumomab tiuxetan